Type 2 Diabetes
Advertisement
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Researchers presented results of an interim analysis of a study of finerenone among patients with CKD and type 2 diabetes.
A study examined the association of ankle-brachial index and CKD progression with type 2 diabetes and elevated BMI.
Is metformin use ever appropriate for patients with advanced kidney disease and type 2 diabetes?
Research examined kidney endpoints between patients with type 2 diabetes after initiating an SGLT2i or GLP-1RA.
A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events.
Monlunabant failed in a study of its use in DKD, but Novo Nordisk had positive news about other kidney treatments in 2024.
The FDA has approved Ozempic (semaglutide) to treat chronic kidney disease (CKD) in adults with type 2 diabetes.
What is the association of gout with CV disease and mortality risk in patients with type 2 diabetes and can CKD modify it?
Effects of SGLT2 inhibitors on renal outcomes in patients with CKD, heart failure, and type 2 diabetes were examined.
Direct comparisons of kidney and cardiovascular outcomes with GLP-1 RAs and SGLT2i in type 2 diabetes are lacking.
Semaglutide reduced the risk of death among patients in the FLOW trial, who had CKD and type 2 diabetes.
FLOW trial data showed semaglutide safely reduced risks of major kidney outcomes regardless of CKD severity.
What is the relationship between blood urea nitrogen-to-serum albumin ratio and mortality in ICU patients with T2D and CKD?
The four-pillar approach to treating diabetic kidney disease (DKD) has been endorsed by high-quality trials, such as FLOW.
The American Heart Association has launched a 4-year plan to improve awareness and treatment of CKM syndrome.
Members of the Nephrology Times editorial board shared the nephrology research and news they’ve found most notable this ...
Researchers conducted an analysis to quantify the within-individual variability of albuminuria in patients with T2D.
FLOW trial results showed that semaglutide has significant benefits for kidney disease events, CV outcomes, and mortality.
Two years after its approval, researchers studied the use of finerenone in adults with type 2 diabetes and CKD.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.